The Organ Donation and Transplantation in Canada System Progress Report 2006–2015, developed collaboratively with Canadian Blood Services organ donation and transplantation advisory committees, provides the most current available national data on deceased and living donation and transplantation performance in Canada. The report presents an overview of the state of the country’s donation and transplantation system today.
Canadian Blood Services currently operates three interprovincial organ sharing programs that serve to maximize transplant access for patients most in need. These include the National Organ Waitlist (NOW), the Kidney Paired Donation (KPD) program and the Highly Sensitized Patient (HSP) program. These programs are operated on the Canadian Transplant Registry (CTR) web-platform, which is maintained by Canadian Blood Services. National data reports providing a comprehensive look at up to 10 years of program performance data can be found below.
Canadian Blood Services works collaboratively with the Canadian tissue community to develop and implement leading practices to improve the quality and safety of tissue produced in Canadian tissue banks. This work includes leading practice workshops, public awareness and education campaigns, national data collection, publication of Canadian eye and tissue banking activity and the design and implementation of recommendations and systematic reviews for five areas of practice for tissue bioburden reduction and control.
This repository aims to support Canadian transfusion medicine health care professionals during the COVID-19 pandemic. It will be updated regularly as new information is available. In addition, the public and donors can learn more about how Canadian Blood Services is responding to COVID-19 by visiting blood.ca/covid-19.
Our work to improve deceased donation in Canada focuses on evolving the quality and safety of national organ donation services, which will result in continued improvement for access to lifesaving organs and transplants for all Canadians.
Alloimmunization is common in patients with sickle cell disease and may complicate transfusion therapy.
Patient phenotyping and prophylactic matching to reduce alloimmunization is recommended.
Transfusion requirements and the presence or absence of red cell antibodies influence recommendations on the extent of phenotyping for patients with sickle cell disease.
Limited evidence exists on the impact of the storage age of blood in this population, but provision of fresh units imposes significant challenges and may compromise availability of optimally phenotype-matched units.